Vasant Narasimhan
Vasant Narasimhan is the chief executive of Novartis, a leading global healthcare company based in Switzerland. He has been with Novartis since 2005, and he became CEO in 2018, where he has focused on advancing the company's research and development efforts while addressing the challenges of the pharmaceutical industry. His leadership comes during a time of significant transformation in healthcare, emphasizing the importance of innovation and patient-centered care.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Switzerland | 2 | 5.00 | 0.18% | +0% | 8,654,622 | 15,736 | $700,000 | 1,273$ |
| Totals | 2 | 8,654,622 | 15,736 | $700,000 | 1,273$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Switzerland:
Vasant Narasimhan is the CEO of Novartis and was present during Trump's speech on drug prices.
5
Switzerland:
Vasant Narasimhan is depicted alongside Sergio Ermotti in a protest image shared by the Juso.
5
Switzerland:
Vasant Narasimhan is the CEO of Novartis, whose strategy is being discussed in the context of the company's performance.
5
Switzerland:
Vasant Narasimhan is the CEO of Novartis and has been with the company since 2005.
8
Switzerland:
Vasant Narasimhan is the CEO of Novartis and has been implementing a strategy of acquiring advanced drug candidates.
5
Switzerland:
Vasant Narasimhan is the CEO of Novartis who received a compensation of over 19 million francs for 2024.
5
Switzerland:
Vasant Narasimhan is the CEO of Novartis and has been noted for his positive surprises in financial presentations.
6
Switzerland:
Vasant Narasimhan is the CEO of Novartis and has called for higher drug prices in Europe.
5
Switzerland:
Vasant Narasimhan is the current CEO of Novartis, whose past acquisition results have been mixed.
5
China:
Vasant Narasimhan is the CEO of Novartis, a globally renowned innovative pharmaceutical company.
8